Sofosbuvir and ABT-450: Terminator of hepatitis C virus?

Table 1 Representative direct acting antiviral agent from 2011 to January, 2013

DAA	HCV genotype	Course of DAA (wk)	Course of therapy (wk)	Dose	With or without pegIFN-α	Published year	Ref.
Telaprevir	1a/1b/1c/unknown	12/8	20/24/44/48	750 mg (tid)	With	2011	[30-32]
Boceprevir	1a/1b/unknown	24/32/44	28/36/48	800 mg (tid)	With	2011	[33-34]
Daclatasvir	1a/1b	24	24	60 mg (qd)	With or without	2012	[36]
Asunaprevir	1a/1b	24	24	600 mg (bid)	With or without	2012	[36]
Sofosbuvir	1/2/3	8/12	8/12	400 mg (qd)	Without	2013	[37]
ABT-450	1a/1b	12	12	250/150 mg (qd)	Without	2013	[38]

qd: Once daily; bid: Twice daily; tid: Thrice daily; DAA: Direct acting antiviral agent; HCV: Hepatitis C virus; pegIFN-α: Peginterferon-α.